By Denny Jacob
Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8% in after-market trading.
TherapeuticsMD, which owns the rights to pharmaceutical royalties, will consider strategic alternatives such as an acquisition, merger or asset sales. Shares rise 4.5% in post-market trading.
Solid Biosciences’ investigational new drug application for a Duchenne Muscular Dystrophy gene therapy candidate was cleared by the Food and Drug Administration. Shares surge 40% in after-market trading.
Write to Denny Jacob at [email protected]
Read the full article here
